Journal of the Neurological Sciences
Volume 226, Issue 1 , Pages 67-70 , 15 November 2004

Treatment of vascular dementia: evidence from trials with non-cholinergic drugs

  • Leonardo Pantoni

      Affiliations

    • Corresponding Author InformationDepartment of Neurological and Psychiatric Sciences, University of Florence, Viale Morgagni 85, 50134 Firenze, Italy. Tel.: +39 55 4277 995; fax: +39 55 4298 461.

References 

  1. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154–1166
  2. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J. Am. Geriatr. Soc. 1989;37:549–555
  3. European Pentoxifylline Multi-Infarct Dementia Study Group. European pentoxifylline multi-infarct dementia study. Eur. Neurol. 1996;36:315–321
  4. Parnetti L, Ambrosoli L, Agliati G, Caratozzolo P, Fossati L, Frattola L, et al. Posatirelin in the treatment of vascular dementia: a double-blind multicentre study vs. placebo. Acta Neurol. Scand. 1996;93:456–463
  5. Marcusson J, Rother M, Kittner B, Rossner M, Smith RJ, Babic T, et al. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement. Geriatr. Cogn. Disord. 1997;8:320–328
  6. Herrmann WM, Stephan K, Gaede K, Apeceche M. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement. Geriatr. Cogn. Disord. 1997;8:9–17
  7. Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T. The scandinavian multi-infarct dementia trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J. Neurol. Sci. 2000;175:116–123
  8. Wilcock G, Mobius HJ, Stoffler A for the MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int. Clin. Psychopharmacol. 2002;17:297–305
  9. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834–1839
  10. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283–1290
  11. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. for the donepezil 307 vascular dementia study group Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323–2330
  12. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479–486
  13. Wallin A, Milos V, Sjögren M, Pantoni L, Erkinjuntti T. Classification and subtypes of vascular dementia. In:  Erkinjuntti T,  Gauthier S editor. Vascular cognitive impairment. London: Martin Dunitz; 2002;p. 27–42
  14. Pantoni L. Subtypes of vascular dementia and their pathogenesis: a critical overview. In:  Bowler J,  Hachinski V editor. Vascular cognitive impairment: preventable dementia. Oxford: Oxford University Press; 2003;p. 217–229
  15. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1:426–436
  16. Inzitari D, Erkinjuntti T, Wallin A, del Ser T, Romanelli M, Pantoni L. Subcortical vascular dementia as a specific target for clinical trials. Ann. N. Y. Acad. Sci. 2000;903:510–521
  17. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al. Limitations of clinical criteria for the diagnosis of vascular dementia in clinical trials: is subcortical vascular dementia a solution?. Ann. N. Y. Acad. Sci. 2000;903:262–272
  18. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al. Research criteria for subcortical vascular dementia in clinical trials. J. Neural Transm., Suppl. 2000;59:23–30
  19. Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the scandinavian multi-infarct dementia trial. J. Neurol. Sci. 2000;175:124–134
  20. Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch. Neurol. 2000;57:191–196
  21. Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. Stroke. 2000;31:2952–2957

PII: S0022-510X(04)00296-5

doi: 10.1016/j.jns.2004.09.014

Journal of the Neurological Sciences
Volume 226, Issue 1 , Pages 67-70 , 15 November 2004

Article Tools